Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Novak, M; Schlagenhauf, A; Bernhard, H; Schweintzger, S; Leschnik, B; Muntean, W.
Effect of rivaroxaban, in contrast to heparin, is similar in neonatal and adult plasma.
Blood Coagul Fibrinolysis. 2011; 22(7): 588-592. Doi: 10.1097/MBC.0b013e328349f190
Web of Science PubMed FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz
Novak Michael Peter
Schlagenhauf Axel
Co-Autor*innen der Med Uni Graz
Bernhard Heike
Leschnik Bettina
Muntean Eugen
Schweintzger Sabrina
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Neonates have lower levels of clotting factors as well as inhibitors. Effects of heparin in neonatal plasma differ from those in adult plasma, and dosage recommendations cannot be extrapolated from adult trials. Riveroxaban is an oral direct factor Xa inhibitor that can achieve an anticoagulant effect without dependence on anti-thrombin. We performed comparative thrombin generation measurements in neonatal cord and adult plasma with different concentrations of unfractionated heparin and rivaroxaban to evaluate the potential of rivaroxaban in neonatal anticoagulation. The impact of heparin or rivaroxaban on the neonatal and adult hemostatic system was determined measuring calibrated automated thrombin generation and activated partial thromboplastin time in platelet-poor plasma pools of 15 adult samples or 15 neonatal cord samples and addition of seven increasing concentrations of heparin or rivaroxaban, respectively, to the pooled samples. Lag time, time to peak and peak height of thrombin generation in neonatal cord samples were significantly less affected by different heparin concentrations than in adult samples, whereas the impact on reduction of endogenous thrombin potential was higher in neonatal cord samples. The impact of rivaroxaban on thrombin generation parameters showed better comparability between neonatal cord and adult samples. Both anticoagulants showed the same differences in activated partial thromboplastin time between adult and neonatal plasma at each concentration. Rivaroxaban shows a very similar pattern in neonatal cord and adult plasma in suppressing thrombin generation and prolonging activated partial thromboplastin time values, suggesting that dose finding may be easier with rivaroxaban in neonates.
Find related publications in this database (using NLM MeSH Indexing)
Adult -
Anticoagulants - pharmacology
Blood Coagulation - drug effects
Factor Xa - analysis
Fetal Blood - chemistry
Heparin - pharmacology
Humans -
Infant, Newborn -
Morpholines - pharmacology
Partial Thromboplastin Time -
Thiophenes - pharmacology
Thrombin - analysis
Thrombin Time -

Find related publications in this database (Keywords)
activated partial thromboplastin time
heparin
neonatal hemostasis
rivaroxaban
thrombin generation
© Med Uni Graz Impressum